Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Vargas

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Health Equity|December 8, 2022
COVID-19 Vaccination Perceptions Among Young Adults of Color in the San Francisco Bay AreaFrancine Rios-Fetchko, Mariam Carson, Mario Gonzalez Ramirez, et al.
Infection Control and Hospital Epidemiology|July 1, 2020
Sustainably reducing device utilization and device-related infections with DeCATHlons, device alternatives, and decision supportEmil P Lesho, Robert Clifford, Kelly Vore, et al.
Plos One|May 13, 2022
COVID-19 vaccination readiness among multiple racial and ethnic groups in the San Francisco Bay Area: A qualitative analysisJonathan Z Butler, Mariam Carson, Francine Rios-Fetchko, et al.
Genetic Testing and Molecular Biomarkers|June 29, 2010
Very low frequencies of Toll-like receptor 2 supposed-2029T and 2258A (RS5743708) mutant alleles in southern Brazilian critically ill patients: would it be a lack of worldwide-accepted clinical applications of Toll-like receptor 2 variants?Helena Strelow Thurow, Cladinara Roberts Sarturi, Paulo Roberto Vargas Fallavena, et al.
Journal of Infection in Developing Countries|March 9, 2020
Trypanosoma cruzi infection in the human population of the Bolivian Chaco: four serosurveys over a 26-year period (1987-2013)Michele Spinicci, Simona Gabrielli, David Rojo, et al.
Plos Neglected Tropical Diseases|September 26, 2019
IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in BoliviaClara Vásquez Velásquez, Graciela Russomando, Emilio E Espínola, et al.
European Radiology|June 9, 2022
Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task forceOliver Lukas Sedlaczek, Jens Kleesiek, Ferdia A Gallagher, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Molecular Cancer|June 9, 2024
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancerRashmi Bharti, Goutam Dey, Debjit Khan, et al.
Cancer Research|October 7, 2022
Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian CancerLaura M Chambers, Emily L Esakov Rhoades, Rashmi Bharti, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Health Equity|December 8, 2022
COVID-19 Vaccination Perceptions Among Young Adults of Color in the San Francisco Bay AreaFrancine Rios-Fetchko, Mariam Carson, Mario Gonzalez Ramirez, et al.
Infection Control and Hospital Epidemiology|July 1, 2020
Sustainably reducing device utilization and device-related infections with DeCATHlons, device alternatives, and decision supportEmil P Lesho, Robert Clifford, Kelly Vore, et al.
Plos One|May 13, 2022
COVID-19 vaccination readiness among multiple racial and ethnic groups in the San Francisco Bay Area: A qualitative analysisJonathan Z Butler, Mariam Carson, Francine Rios-Fetchko, et al.
Genetic Testing and Molecular Biomarkers|June 29, 2010
Very low frequencies of Toll-like receptor 2 supposed-2029T and 2258A (RS5743708) mutant alleles in southern Brazilian critically ill patients: would it be a lack of worldwide-accepted clinical applications of Toll-like receptor 2 variants?Helena Strelow Thurow, Cladinara Roberts Sarturi, Paulo Roberto Vargas Fallavena, et al.
Journal of Infection in Developing Countries|March 9, 2020
Trypanosoma cruzi infection in the human population of the Bolivian Chaco: four serosurveys over a 26-year period (1987-2013)Michele Spinicci, Simona Gabrielli, David Rojo, et al.
Plos Neglected Tropical Diseases|September 26, 2019
IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in BoliviaClara Vásquez Velásquez, Graciela Russomando, Emilio E Espínola, et al.
European Radiology|June 9, 2022
Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task forceOliver Lukas Sedlaczek, Jens Kleesiek, Ferdia A Gallagher, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Molecular Cancer|June 9, 2024
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancerRashmi Bharti, Goutam Dey, Debjit Khan, et al.
Cancer Research|October 7, 2022
Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian CancerLaura M Chambers, Emily L Esakov Rhoades, Rashmi Bharti, et al.
Pageof 13